| Recruiting | Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose NCT07003295 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantl NCT06675123 | City of Hope Medical Center | Phase 1 |
| Recruiting | Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minoritie NCT06859008 | City of Hope Medical Center | Phase 1 |
| Recruiting | Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lym NCT06839053 | Fred Hutchinson Cancer Center | Phase 2 |
| Withdrawn | Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy NCT05936229 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19 NCT06343376 | Roswell Park Cancer Institute | Phase 1 |
| Recruiting | B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cycloph NCT06191887 | Mayo Clinic | Phase 1 |
| Recruiting | Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma NCT05910801 | Academic and Community Cancer Research United | Phase 2 |
| Recruiting | Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies NCT05453396 | University of Washington | Phase 2 |
| Withdrawn | Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lym NCT04635683 | Yazeed Sawalha | Phase 1 |
| Active Not Recruiting | Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma NCT04939272 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Recruiting | Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intol NCT05249959 | Fondazione Italiana Linfomi - ETS | Phase 2 |
| Withdrawn | Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma NCT04990778 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma NCT05025800 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL NCT04995536 | City of Hope Medical Center | Phase 1 |
| Terminated | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refrac NCT04659044 | Academic and Community Cancer Research United | Phase 2 |
| Completed | Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy NCT04703686 | The Lymphoma Academic Research Organisation | Phase 2 |
| Completed | Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies i NCT04872413 | M.D. Anderson Cancer Center | N/A |
| Recruiting | Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle NCT04484012 | City of Hope Medical Center | Phase 2 |
| Completed | CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymph NCT04578600 | Joseph Tuscano | Phase 1 |
| Terminated | CD19-Specific T Cells Post AlloSCT NCT03579888 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in P NCT04205409 | University of Washington | Phase 2 |
| Active Not Recruiting | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphom NCT04007029 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Terminated | Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT04047797 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT03946878 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients Wit NCT04054167 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lympho NCT03219047 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Completed | Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or NCT03440567 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma NCT03479268 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Exp NCT03277729 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma NCT03147885 | Barbara Ann Karmanos Cancer Institute | Phase 1 / Phase 2 |
| Completed | Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma NCT03061188 | Northwestern University | Phase 1 |
| Completed | Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymp NCT03206970 | BeiGene | Phase 2 |
| Active Not Recruiting | Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma NCT03015896 | David Bond, MD | Phase 1 / Phase 2 |
| Completed | Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma NCT02950220 | Kami Maddocks | Phase 1 |
| Completed | Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma NCT02568553 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant NCT02869633 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Completed | Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma NCT02736617 | OHSU Knight Cancer Institute | Phase 2 |
| Terminated | Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL NCT02572453 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT02420795 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT02489123 | University of Washington | Phase 2 |
| Active Not Recruiting | Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin NCT02051257 | City of Hope Medical Center | Phase 1 |
| Completed | Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients NCT01921387 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma NCT01955499 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas NCT01897012 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patient NCT01880567 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non- NCT01865617 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma NCT01719250 | Mayo Clinic | EARLY_Phase 1 |
| Active Not Recruiting | Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or NCT01695941 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or R NCT01381692 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer NCT00723099 | Fred Hutchinson Cancer Center | Phase 2 |